Clinical Efficacy of Edaravone and Urinary Kallidinogenase Co-Treatment in Acute Ischemic Stroke

被引:0
作者
Pan, Xiaoxiao [1 ]
Gong, Xiaoqian [1 ]
Pan, Lili [2 ]
Lu, Liyu [1 ]
机构
[1] Xuzhou Med Univ, Peoples Hosp Yancheng 1, Yancheng Clin Coll, Dept Neurol, Yancheng 224006, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Peoples Hosp Yancheng 1, Yancheng Clin Coll, Dept Ultrasound Diag, Yancheng 224006, Jiangsu, Peoples R China
关键词
Edaravone; uric acid; combination therapy; acute ischemic stroke; clinical efficacy; ALTEPLASE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To evaluate the clinical effectiveness of utilizing edaravone in conjunction with uric acid in treating acute ischemic stroke. Between January 2021 and January 2023, 120 individuals with acute ischemic stroke were admitted to the neurology department of our hospital and were subsequently divided into the observation group and the control group through random assignment. Edaravone monotherapy was utilized in the control group, while the observation group received a combination treatment of edaravone and uric acid. Prior to treatment and post-treatment, the levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in the bloodstream were analyzed, while also documenting the overall effective rate and the occurrence of adverse reactions. Post-treatment, a considerable decline was observed in national institutes of health stroke scale and activities of daily living scores for both groups in comparison to their respective pre-treatment scores. Furthermore, the observation group displayed significantly lower national institutes of health stroke scale and activities of daily living scores compared to the control group after treatment, with a p<0.05. The observation group exhibited a remarkably higher overall effective rate compared to the control group, with statistical significance (p<0.05). Additionally, post-treatment, the levels of inflammatory factors in the observation group were notably lower as opposed to the control group. There was no statistically significant distinction in the incidence of adverse reactions between the two groups (p>0.05). The co-administration of edaravone and uric acid in treating acute ischemic stroke may effectively mitigate brain tissue damage by modulating the body's inflammatory response. As a result, it facilitates neurological recovery and enhances the daily living abilities of patients. The significant advantages derived from this treatment approach underscore the importance of promoting its implementation.
引用
收藏
页码:154 / 158
页数:5
相关论文
共 19 条
[11]  
Micieli G, 2009, VASC HEALTH RISK MAN, V5, P397
[12]  
Niu J, 2022, Henan Med Res, V31, P4545
[13]  
Su Z, 2018, Chin J Geriatr, V37, P4
[14]  
Wang G, 2013, Int J Neurol Neurosurg, V2, P4
[15]  
Wang G, 2017, Henan Med Res, V26, P2
[16]  
Yao M, 2023, Clin Toxicol, V38, P5
[17]  
Zheng S, 2018, Chin J Pharmacol Toxicol, V32, P12
[18]  
Zhu M, 2020, Heilongjiang Med, V44, P2
[19]  
Zong J, 2014, Contemporary Med, V5